富马酸酮替芬滴眼液治疗季节变应性结膜炎眼痒及结膜充血的疗效观察

目的 探讨0.025%富马酸酮替芬滴眼液治疗季节性变应性结膜炎患者眼痒、结膜充血的临床疗效.方法 采用多中心、双盲、随机、平行组别的研究方法,将诊断为季节性变应性结膜炎的229例(229只眼)患者随机分为试验组114例,给予进口0.025%富马酸酮替芬滴眼液,对照组115例,给予0.05%依美斯汀滴眼液,均为2次/d,每次1滴,疗程14d.在用药前和用药后(7±1)d,(14±1)d对两组患者的眼痒和结膜充血进行观察评分.结果 用药后(7±1)d以及(14±1)d,酮替芬组和依美斯汀组眼痒、结膜充血评分均明显下降,与基线期相比差异有统计学意义(P＜0.05);眼痒和结膜充血下降幅度组间(酮替芬一依美斯汀)差异无统计学意义(P＞0.05).结论 进口0.025%富马酸酮替芬滴眼液治疗季节性变应性结膜炎患者的眼痒、结膜充血疗效非劣效于0.05%依美斯汀滴眼液.     

春季卡他性结膜炎的药物治疗疗效观察

目的临床观察0.1%盐酸奥洛他定滴眼液联合那素达滴眼液治疗春季卡他性结膜炎的疗效。方法对169例患者应用奥洛他定滴眼液滴眼2次/日,共1.5～3个月;那素达滴眼液3次/日点眼,共1个月。于治疗后3、7、14、28 d,2个月、3个月随访观察。结果联合用药后7 d 84.2%的结膜充血消失,14 d时79.7%的眼痒、烧灼感、畏光流泪等症状消失,3个月时治愈率达98.7%。结论奥洛他定联合那素达滴眼液可快速、持久稳定的控制春季卡他性结膜炎的症状及体征。     

那素达治疗春季卡他性结膜炎疗效观察

本科自 2 0 0 2年 2月采用爱尔康公司生产的那素达滴眼液治疗春季卡他性结膜炎 3 3例 (66只眼 ) ,获得较好效果 ,现报告如下。一、临床资料本组 3 3例 (66只眼 ) ,均来自我科门诊 ,男 2 0例 ,女 13例 ,年龄 10～ 40岁 ,平均 2 0 .5岁。类型 :睑结膜型 18例 ,角膜缘型 11例 ,混合型 4例。临床特征 :眼部奇痒 ,可有眼睑沉重、灼热感、异物感及畏光、流泪伴有上睑结膜乳头肥大 ,角膜缘有胶样增生。发病多与季节有关。治疗 :本组病例治疗期间停止其它一切药物治疗。采用那素达点眼 ,每次 1～ 2滴 ,每日 4～ 6次 ,连续用药 7～ 14天。显效 :自觉…     

0.1％普拉洛芬滴眼液治疗急性变态反应性结膜炎的疗效

目的评价0．1％普拉洛芬滴眼液治疗急性变态反应性结膜炎的有效性及安全性。方法60例（120眼）急性变态反应性结膜炎患者,包括季节性与常年性变态反应性结膜炎．随机分成两组：对照组单用0．05％富马酸依美斯汀滴眼液．试验组联合应用0．1％普拉洛芬滴眼液与0．05％富马酸依美斯汀滴眼液,两组用药均为每日3次。治疗前与治疗后第1天、第4天、第7天、第14天进行随访,评估眼痒、流泪、畏光、异物感等症状与睑结膜乳头和滤泡、分泌物、结膜充血、结膜水肿、角膜缘改变、角膜上皮改变、球周组织水肿等体征,评价有效率及治愈率,并观察用药后不适感与副作用。结果两组患者的一般情况、治疗前症状与体征评分差异均无统计学意义（P〉0．05）。对照组与试验组的总评分值在治疗后第1天分别为20.30±4．69与12．53±4．12．第4天分别为16．85±3．95与5．93±3．06．第7天分别为12．00±4．26与3．07±3．19,第14天分别为9．45±5．28与1．40±2．46,差异均有统计学意义（P〈0．01）。对照组与试验组在治疗7d后有效率分别为53.3％与100．0％。治愈率分别为6．7％与46．7％;治疗14d后有效率分别为73.3％与100．0％．治愈率分别为10．0％与73．3％．差异均有非常显著的统计学意义（P〈0．01）。试验组未见明显用药后不适感与副作用。结论0．1％普拉洛芬滴眼液能快速、有效地缓解急性变态反应性结膜炎的症状与体征,是一种有效而安全的变态反应性结膜炎的治疗药物。     

0. 02% 氟米龙联合玻璃酸钠治疗中度干眼的临床研究

目的观察0．02％氟米龙滴眼液联合玻璃酸钠滴眼液治疗中度干眼的临床疗效。方法将2012年6月-2012年10月在复旦大学附属眼耳鼻喉科医院眼科门诊诊断为中度干眼的41例（41眼）患者随机分成A、B2组,A组给予0．02％氟米龙联合玻璃酸钠滴眼液,B组单独应用玻璃酸钠滴眼液,观察2组患者在用药前、治疗14d后及治疗28d后的眼表疾病指数OSDI评分、结膜充血评分、角膜荧光素染色评分、泪膜破裂时间（BUT）、基础泪液分泌试验（SIt）及睑板腺分泌物评分。结果用药28d后,A组和B组干眼患者在OSDI评分、结膜充血评分、角膜荧光素染色评分、BUT、SIt及睑板腺分泌物评分上均有明显改善（P〈0．05）;A组比B组更有助于结膜充血评分及睑板腺分泌物评分的改善（P〈0．05）。结论氟米龙联合玻璃酸钠滴眼液能减轻眼表的炎性充血,改善睑板腺功能。     

过敏性结膜炎的临床特点

目的　了解国人过敏性结膜炎的临床特点。方法　对临床已确诊为过敏性结膜炎的患者 84例 16 1眼症状及体征量化评分后进行分析。结果　 84例 16 1眼过敏性结膜炎患者 ,平均年龄 (38.6 1± 12 .72 )岁 ,男 2 8例 ,女 5 6例 ,平均病情积分 11.79± 4 .36 ,其中急性过敏性结膜炎 77例(91.6 7% ) 14 8眼 ,慢性过敏性结膜炎 7例 (8.33% ) 13眼 ,两者的病情评分比较有显著差异 (P<0 .0 1)。过敏性结膜炎最常见症状为眼痒 (10 0 .0 0 % ) ,最常见的体征为结膜充血(10 0 .0 0 % )。2 6 .19%的患者伴有眼外过敏性疾病病史。结论　过敏性结膜炎是一类以青中年女性发病为主 ,以眼痒及结膜充血为主要临床特点而对角膜通常没有明显影响的非感染性眼表疾病     

双氯芬酸钠透明质酸钠滴眼液治疗急性变态反应性结膜炎评价

目的 评价0.1%双氯芬酸钠透明质酸钠滴眼液辅助治疗急性变态反应性结膜炎的有效性及安全性的临床评价.方法 对90例(180只眼)急性变态反应性结膜炎患者.包括季节性与常年性变态反应性结膜炎,随机分成三组.A组:对照一组,单用0.05%依美斯汀滴眼液;B组:对照二组,0.05%依美斯汀滴眼液联合0.1%普拉洛芬滴眼液;C组:试验组0.05%依美斯汀滴眼液联合0.1%双氯芬酸钠透明质酸钠滴眼液,三组每种用药均为每日3次.分别于治疗前与治疗后1d、4d、7d、14d随访,评估眼痒、流泪、畏光、异物感等症状与睑结膜乳头和滤泡、分泌物、结膜充血、结膜水肿、角膜缘改变、角膜上皮改变、球周组织水肿等体征,评价有效率及治愈率,并观察用药后眼部不适及副反应.结果 三组患者的一般情况、治疗前症状与体征评分差异均无统计学意义(P＞0.05).A组、B组与C组的治疗有效率在治疗后第1天分别为6.7%、56.7%与60.0%,第4天分别为20.0%、100.0%与96.7%,第7天分别为53.3%、100.0%与100.0%,第14天分别为73.3%、100.0%与100.0%.治疗第14天治愈率分别为10.0%、73.3%与63.3%.两两比较各随访时间点的有效率与治愈率,A组与B组的组间差异均具有统计学意义(P均＝0.000),A组与C组组间的差异均具有统计学意义(P均=0.000),而B组与C组在治疗后各随访时间点的有效率与治愈率相当,差异无统计学意义(P=0.918、0.147、0.058、0.0405＞0.05).各试验组未见用药后的眼部不适及副反应.结论 非甾体类消炎药能快速、有效缓解急性变态反应性结膜炎的症状与体征,其中,0.1%双氯芬酸钠透明质酸钠滴眼液与同类进口滴眼液的疗效相当,是一种有效、安全又经济的变态反应性结膜炎的辅助治疗药物.     

润洁萘扑维滴眼液治疗视疲劳的初步临床观察

目的 :评价润洁萘扑维滴眼液治疗视疲劳的临床效果。方法 :应用润洁萘扑维滴眼液治疗 4 2例视疲劳者 ,分别于用药前、用药后 1d、用药后 3d、用药后 7d、用药后 1 4d评估患者的症状和体征 ,同时观察药物的不良反应 ,进行评分。结果 :与用药前相比 ,总积分 (P <0 .0 0 0 )、异物感 (P =0 .0 0 3)、烧灼感 (P =0 .0 0 4 )、眼痛 (P =0 .0 0 6 )、流泪 (P =0 .0 1 4 )、充血 (P =0 .0 1 )等指标的积分于用药后 1d下降 ,差异有显著性。畏光 (P =0 .0 0 1 )、睑痉挛 (P =0 .0 2 6 )、头晕头痛(P =0 .0 0 5)积分于用药后 3d下降 ,差异有显著性。除头晕头痛指标积分有反弹外 (用药后 7d和 1 4d ,P >0 .0 5) ,其余指标的积分均随着时间延长而逐渐下降。恶心呕吐症状在用药观察期间无明显改变。有 8例发生一过性眼局部不良反应 ,其中 1例伴有轻微的头痛。结论 :润洁萘扑维滴眼液1 4d内能安全有效地缓解视疲劳的一些症状和体征。     

新生儿结膜炎诊断及治疗措施探讨

目的:探讨新生儿结膜炎的诊断及治疗措施。方法:将我院2008-01/2010-01收治的新生儿结膜炎患者100例179眼按入院时间顺序随机分为观察组与对照组,每组50例,观察组给予氧氟沙星滴眼液,对照组给予青霉素滴眼液,观察比较两组患儿的疗效、眼分泌物消失时间、结膜充血消失时间、角膜透明时间。结果:治疗后,观察组患儿中有效率为98.0%,显著高于对照组患儿的88.0%(χ2=3.84,P<0.05);观察组患儿的眼分泌物消失时间、结膜充血消失时间、角膜透明时间均明显短于对照组患儿(P<0.01)。结论:氧氟沙星滴眼液治疗新生儿结膜炎疗效极佳,可有效提高治愈率,并缩短患儿的眼分泌物、结膜充血消失时间及角膜透明时间。     

鱼腥草滴眼液治疗流行性角膜结膜炎的临床观察

目的:观察鱼腥草滴眼液治疗流行性角膜结膜炎的临床效果。方法:收集2005-07/2005-09同仁医院门诊急诊就诊的临床确诊为流行性角膜结膜炎的患者40例,随机分为观察组和对照组,分别给予鱼腥草滴眼液和1g/L阿昔洛韦滴眼液点眼,观察6项眼部症状及体征的变化并评分,进行统计学分析。结果:在总的显效率上,两组间差异有统计学意义(P<0.01),观察组优于对照组。用药后第7d,在结膜充血的改善上观察组和对照组间差异有统计学意义(P<0.05);用药后14d,在畏光、异物感、流泪以及结膜充血的改善上两组差异均有统计学意义(P<0.05〉。结论:鱼腥草滴眼液对于治疗流行性角膜结膜炎有明显效果,其疗效优于1g/L阿昔洛韦滴眼液。     

Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate

OBJECTIVE: To compare the clinical efficacy and tolerance of 0.1% olopatadine hydrochloride (OHC) versus 0.05% ketotifen fumarate (KF) in the management of allergic conjunctivitis. MATERIALS AND METHODS: Eighty adult patients with a history of allergy (allergic conjunctivitis, hay fever, asthmatic bronchitis and dermatitis) that were showing allergic conjunctivitis signs and symptoms (itching, hyperemia, mucous discharge and tearing) at the time of inclusion in this study were evaluated. Patients were divided in two groups, A and B. Group A patients were treated with OHC and group B patients were treated with KF. Both groups received one drop in the affected eye every 12 hrs. The start time of this study was the first patient visit, in which the medication was instilled for the first time. Both groups of patients were evaluated 30 min, 48 hr., 7 days and 14 days later. Local tolerance of each medication was evaluated. RESULTS: Clinical improvement of the signs and symptoms of allergic conjunctivitis occurred in 42.5% to 62.5% of the patients in Group A when assessed 30 min following the first topical ocular dose of olopatadine. However, mucous discharge was not affected. Forty-eight (48) hrs. after the first instillation, improvements in 57.5% to 75% of the patients were shown in every evaluated parameter. After 7 days of treatment, positive clinical results were observed in 80% to 87.5% of the treated patients. Except for the patients that were dismissed from the study before the seventh day of treatment due to the absence of therapeutic response (4/40), all patients satisfactorily completed the therapeutic plan by the seventh day. No intolerance reactions were observed in patients of this group. In Group B patients (KF), clinical improvement of the signs and symptoms measured in the study was shown in 20.0% to 47.5% 30 min after instillation. As observed with olopatadine, no improvement in the number of patients showing mucous discharge was noted at the 30-min time point. At 48 hr. after the first instillation, 27.5% to 48% of patients showed improvement in every evaluated parameter. After 7 days of treatment, improvement was observed in 60% to 75% of patients. On Day 14, positive responses were observed in 67.5% to 75% of patients. Seventeen and one-half percent of the patients were dismissed from the study before the seventh day of treatment due to the absence of a therapeutic response. Approximately 23% of the patients had mild reactions of intolerance (stinging) which was not a cause to discontinue the treatment. CONCLUSION: Olopatadine hydrochloride controlled allergic conjunctivitis symptoms and signs more rapidly and to a greater extent than ketotifen fumarate. Fewer cases of treatment failure were noted with OHC, and no local intolerance reactions were observed, while KF triggered mild reactions (stinging) in 23% of patients.     

Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis

PURPOSE: The efficacy and safety of emedastine 0.05% eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H(1) antagonist, were studied in comparison to levocabastine 0.05% eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. RESULTS: Both emedastine and levocabastine produced a statistically significant (P =.0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. CONCLUSIONS: Emedastine 0.05% eye drops administered twice daily are more efficacious than levocabastine 0.05% eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05% eye drops and levocabastine 0.05% eye drops were well tolerated.     

Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis

PURPOSE: To study the safety and efficacy of the topical corticosteroid, desonide 0.25% ophthalmic solution, for inhibition of the clinical allergic reaction induced by conjunctival provocation (CPT) and for the treatment of seasonal allergic conjunctivitis (SAC). METHODS: For the CPT study, 12 allergic but inactive patients were exposed in both eyes to increasing doses of a specific allergen until a positive bilateral, symmetrical early- and late-phase reaction was obtained. After 2 weeks the last positive dose was readministrated and their positive response confirmed. After an additional 2 weeks, CPT was performed 30 minutes after topical administration of desonide in one eye and placebo in the contralateral eye (Group A) or after topical desonide or placebo four times a day for 2 days (Group B). Clinical signs and symptoms were recorded after 15, 30, and 60 minutes, and after 6 hours. Regarding the seasonal study, 96 patients with active SAC were treated bilaterally with either desonide or fluorometholone for 3 weeks, and allergic signs and symptoms evaluated at regular intervals. The safety of the drugs was assessed by identification of any side effects or adverse events of any kind. RESULTS: For the CPT study: individual itching and redness, and the sum score for signs and symptoms were all statistically (p < 0.05) and clinically (greater than 1 change between treated eyes) significantly lower in desonide versus placebo eyes. Both early- and late-phase reactions were reduced by desonide pretreatment. Seasonal study: desonide and fluorometholone were both highly effective in reducing itching, tearing, and conjunctival hyperemia over time (p < 0.0001). Both drugs appeared safe, with no statistically significant changes in IOP observed with either treatment. CONCLUSIONS: Desonide has a significant therapeutic effect on both the induced conjunctival early- and late-allergic reaction and in active SAC. It was also safe, with no side effects such as increases in intraocular pressure observed by physician or patient.     

Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy

OBJECTIVE: The efficacy of Patanol, a topically applied anti-allergic agent, was evaluated in a group of patients with allergic conjunctivitis due to contact lens wear (GROUP I) and a group comprised of seasonal allergic conjunctivitis patients, vernal conjunctivitis patients and atopic keratoconjunctivitis patients (GROUP II). METHODS: One drop of Patanol was administered to each eye twice daily. Signs and symptoms were assessed 7, 14, and 28 days after initiation of drug therapy. RESULTS: Itching/burning, tearing, hyperemia and papillary reaction were reduced to scores of 0/1 (absent/mild) in 85%, 90%, 81% and 62%, respectively, of GROUP I patients at Day 28. The allergic conditions in GROUP II patients also improved with Patanol treatment. Itching/burning, tearing, hyperemia and papillary reactions were absent/mild in 60%, 76%, 96% and 90%, respectively, of these patients at Day 28. CONCLUSION: Patanol treatment effectively and rapidly alleviated the signs and symptoms of allergic conjunctivitis due to contact lens wear as well as vernal conjunctivitis, atopic keratoconjunctivitis and the common seasonal allergic conjunctivitis. Patanol allowed allergic patients to be more comfortable while permitting them to continue using contact lenses.     

Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis

BACKGROUND: This study evaluated the conjunctival effects of latanoprost and timolol, both of which contain benzalkonium chloride, in patients with primary open-angle glaucoma (POAG), with and without a history of allergic conjunctivitis (AC). METHODS: Two groups of 25 patients with and without a positive history for AC were studied. After a 21-day wash-out period patients were randomized to 14 days treatment with latanoprost or with timolol, in a cross-over fashion. The following parameters were evaluated on days 0 and 14: number of white blood cells, ferning test, conjunctival impression cytology, subjective symptoms, and objective ocular changes. RESULTS: Latanoprost caused: (a) an increase in eosinophils in both groups and reduction in lymphocytes only in the group with a history of AC; (b) alterations in ferning test and impression cytology only in AC patients; and (c) development of subjective symptoms and objective signs only in non-AC glaucomatous subjects. Timolol therapy was responsible only for the occurrence of subjective symptoms and objective signs in non-AC patients. CONCLUSION: Latanoprost treatment induces ocular surface changes which are more evident in POAG patients who are also affected by AC. These findings are probably related to the very high latanoprost concentration of benzalkonium chloride and to its bedtime administration, which further amplifies the toxicity.     

A randomized,double-masked,placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis

ObjectiveTo evaluate the effects of loteprednol etabonate (LE) 0.2% in reducing the signs and symptoms of seasonal allergic conjunctivitis.DesignRandomized, double-masked, placebo-controlled, parallel group multicenter study of 6 weeks duration.ParticipantsA total of 135 patients with signs and symptoms of seasonal allergic conjunctivitis participated.InterventionAll patients received either LE 0.2% or placebo (vehicle) four times a day in both eyes for 42 days.Main outcome measuresBulbar conjunctival injection (primary sign) and itching (primary symptom) over the first 2 weeks of treatment was measured.ResultsA reduction in severity was seen in both LE and placebo groups for bulbar conjunctival injection (1.5 vs. 1.0 units on a 0–3 scale) and itching (3.4 vs. 3.0 units on a 0–4 scale) over the first 2 weeks. The treatment effect by these measures was −0.5 and −0.4 units in favor of LE (P ≤ 0.008). Resolution (i.e., the proportion of patients with signs or symptoms no longer present) at day 14 strongly favored LE-treated patients (36% and 15%; 58% and 38%, for injection and itching, respectively).Both treatments were well tolerated. One patient in each treatment group (1 of 67 and 1 of 68, respectively) had an elevation of intraocular pressure of 10 mmHg or greater during the 6 weeks of treatment.ConclusionsLoteprednol etabonate 0.2% was more effective than placebo in the treatment of seasonal allergic conjunctivitis. Loteprednol etabonate 0.2% had a safety profile comparable to placebo.